Palmitoyl tripeptide-8 is a synthetic bioactive peptide consisting of a specific tripeptide sequence (His-D-Phe-Arg-NH₂) linked through an amide bond to a palmitoyl group. The addition of this palmitoyl group significantly increases the peptide’s lipophilicity; thereby enhancing stability within various cosmetic matrices and facilitating penetration into the stratum corneum of the skin.

More effective interaction with skin cells is a direct result of this capability.

Sequence

Pal-His-D-Phe-Arg-NH2

CAS Number

936544-53-5

Molecular Formula

C37H61N9O4

Molecular Weight

695.94 g/mol

Research Of Palmitoyl Tripeptide-8

Palmitoyl Tripeptide-8 functions as a bioinspired peptide – partially mimicking a tripeptide fragment of α-melanocyte stimulating hormone (α-MSH). Competitive binding to melanocortin receptor 1 (MC1R) is its key mechanism; inhibition of the subsequent release of several inflammatory mediators (IL-8 being a prime example, TNF-α among others) reduces the overall inflammatory response.

Both in vitro and clinical trials have shown significant anti-inflammatory and substantial anti-irritant effects.

Multiple independent in vitro studies confirm the effective suppression of various pro-inflammatory cytokines. Downregulation of IL-8 from keratinocytes (UVB or other irritant induced) is well documented. All other previously mentioned mediators are at least partially inhibited.

IL-1 and TNF-α in particular are seen as ‘upstream’ inflammatory factors; Palmitoyl Tripeptide-8’s ability to interrupt this cascade is what sets it apart as a truly effective, and to date unique, anti-inflammatory agent.

Palmitoyl Tripeptide-8 reduces vasodilation, edema, and erythema; anti-inflammatory and soothing effects are well documented. Clinical studies have shown that formulations containing this peptide significantly mitigate various inflammatory skin responses – reduced vasodilation being one of the more measurable outcomes, tissue edema being another.

Irritation specific symptoms (redness, burning being prime examples) are directly linked to these observations. Sunscreen studies utilizing the ingredient report a clear significant reduction in the visible, sun-induced erythema following use.

A more specialized clinical trial on erythema papulosum patients saw multiple improvements; skin flushing, dryness, marked elimination of edema, and stinging sensation significantly lessened.

Product efficacy measures followed suit – skin redness, all forms of flushing, tone, severity of the condition itself, radiance and overall appearance of the skin all showed statistically significant positive changes.

In summary, Palmitoyl Tripeptide-8 is a core ingredient within sensitive skin care. Anti-inflammatory, anti-allergic, and barrier repair functions are all supported by current research.

Scientific synthesis of the peptide itself ensures its safety and efficacy.